This inventor holds 32 USPTO granted patents and 6 published patent applications and 2 EPO patents, primarily in Selective Androgen Receptor Modulators. Top assignees: The University of Tennessee Research Foundation, Gtx Corporation, Oncternal Therapeutics, Inc.. Active years: 2002-2025.
Location History:
- Florence, SC (US) (2002 - 2006)
- Germantown, TN (US) (2007 - 2024)
Company Filing History:
28 out of 785 
7 out of 55 
1 out of 16 
Years Active: 2002-2025
Areas of Expertise:
Title: Yali He: Innovator in Selective Androgen Receptor Degraders
Introduction
Yali He, based in Germantown, TN, is a prolific inventor with an impressive portfolio of 31 patents. His innovations primarily focus on selective androgen receptor degraders (SARD), showcasing his dedication to advancing medical treatments for serious conditions such as various types of cancer.
Latest Patents
Among his latest patents, Yali He has developed selective androgen receptor degrader (SARD) ligands and methods of use that are aimed at treating prostate cancer, advanced prostate cancer, castration-resistant prostate cancer, and triple negative breast cancer. These inventions involve complex compounds based on pyrrole, pyrazole, imidazole, triazole, and morpholine, specifically targeting the androgen receptor and its variants that can contribute to resistance against treatments. His work also addresses other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, illustrating the wide-ranging implications of his research.
Career Highlights
Yali He has contributed his expertise to reputable organizations, including the University of Tennessee Research Foundation and GTx Corporation. His tenure at these institutions has enabled him to further his research and innovation in the field of pharmacology and oncology.
Collaborations
Throughout his career, Yali has collaborated with notable professionals such as Duane Douglas Miller and James T Dalton. These partnerships have likely contributed to his successful patent applications and the advancement of innovative treatments.
Conclusion
Yali He stands out as a significant contributor to the field of medical research, particularly through his work on selective androgen receptor degraders. With a strong record of patents and influential collaborations, he is paving the way for new therapeutic options in treating cancer and other critical health issues. His continued commitment to innovation promises to have a lasting impact on medical science.